Skip to main content
-

IBA Reports Full Year 2022 Results

ALL-TIME RECORD ORDER INTAKE AND BACKLOG IBA ANNOUNCES MID-TERM GUIDANCE Louvain-la-Neuve, Belgium, 23 March 2023 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2022 financial year.    Financial summary All-time record annual Equipment order intake of EUR 456 million and Dosimetry order intake of EUR 67 million All-time record overall Equipment and Services backlog of EUR 1.4 billion including Equipment backlog of EUR 713 million an Services backlog of EUR 669 million Total 2022 Group revenues up 15% from 2021 to EUR 361.3 million  Proton Therapy and Other Accelerators Services revenue increased 12.8% versus last year to EUR 135 million Gross margin was 35.1%, compared to 34.4% in 2021 Positive 2022 REBIT of EUR 11.1 million, down from EUR 14.5 million in 2021, due to the high inflationary environment, as well as increased investment into R&D, infrastructure, digital technologies and sustainability to maintain IBA’s leading offering and invest in its future growth Total Group net profit of EUR 6.1 million (2021: EUR 3.9 million), positively impacted by deferred tax assets recognition related to improvement of future profitability Strong balance sheet with EUR 158 million gross and EUR 117 million net cash  Mid-term guidance announced and dividend of EUR 0.21 per share proposed by the Board, a 10% increase from last year    Business summary  17 new proton therapy rooms sold in 2022, compared to nine last year Other Accelerators order intake of 36 systems compared to 31 in 2021 Dosimetry order intake up 22% to a record EUR 67 million Three new installations in PT and 32 installations in Other Accelerators started during the year with four completed in PT and 20 in Other Accelerators Good progress across IBA’s four strategic sustainability streams: a) low carbon, low waste products b) low carbon, low waste company c) diverse equitable and inclusive workplace and d) accountability towards sustainability  Olivier Legrain, Chief Executive Officer of IBA, commented: “Despite the headwinds from the global macro-economic environment, IBA has seen another strong year, driven by increasing sales across all of its business units and an all-time record order intake and backlog. On the Proton Therapy side, we have seen significant traction in Europe and the US in 2022. In addition, I’m pleased with the continued pace of deals within Industrial Solutions especially, which has continued into the start of 2023. During the year we have also been focused on future-proofing the business with targeted investments to support the Group in executing on its record backlog as well as maintaining our leading market position. With our strong backlog, good revenue visibility and high cash position, we are confident on IBA’s positive outlook for 2023 and beyond.”   
See more
-

IBA Business Update – Third Quarter 2022

Louvain-La-Neuve, Belgium, 17 November 2022 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 September 2022.   Group Overview Business operations continue to be strong, with good performance across all four business units Exceptional group order intake of EUR 260 million at 30 September for 2022 to date, compared to EUR 133 million for the first nine months of 2021, driven by strong performance across the business, particularly within Industrial Solutions Backlog remains high at EUR 1.2 billion and new tenders continue to progress internationally for all business units Strong balance sheet with (unaudited) net cash position of EUR 134 million (30 June 2022: 137 million)   Olivier Legrain, Chief Executive Officer of IBA commented: “IBA has continued to see solid performance in the third quarter across all business units, both in terms of contract wins, technological advances and supported by targeted value driving acquisitions. We have been especially pleased to see continued momentum in Industrial Solutions, with the business unit passing a key milestone of EUR 100 million order intake to date this year. Within proton therapy we are seeing market dynamics shifting favorably with demand building in all regions globally and resulting in IBA winning strategically significant, high-value contracts. Looking ahead, whilst some challenges remain, the strategies and investments we are making are positively impacting and we are confident in the longer-term performance of the Group, underpinned by a strong balance sheet that we will continue to utilize for investment in future growth.”   Proton Therapy 24 projects ongoing in Proton Therapy, with nine Proteus®PLUS1 and 15 Proteus®ONE1 systems in progress An active global pipeline, highlighting the strength of proton therapy market across all geographies A total of 40 service contracts now generating recurring revenues globally IBA qualified as the only supplier for the second round of significant tender to provide ten proton therapy units across Spain Multi-year research collaboration signed with Fred Hutchinson Cancer Center and the University of Washington (UW), Seattle, for ConformalFLASH®2 Proton Therapy Collaboration agreement signed with Apollo Hospitals Enterprise Ltd (AHEL) The PROTECT-trial consortium enrolled the first patient in a trial investigating proton therapy in oesophageal cancer Other Accelerators (RadioPharma, Industrial) Other Accelerators continued to perform strongly in Q3, with eight new systems sold in the period. A total of 29 systems have been sold in the first nine months of 2022, compared to 23 for the same period last year Exceptional performance by Industrial Solutions, with the business reaching the milestone of EUR 100 million order intake to date Collaboration deal agreed with Chengdu New Radiomedicine Technology Co., Ltd (CNRT) to install a Cyclone® IKON in Chengdu, Sichuan Province, China Agreement signed with NorthStar Medical Radioisotopes for two additional Rhodotron® electron beam accelerators for commercial production of radioisotopes Launched Pantera, a joint venture with SCK CEN to produce actinium-225, one of the most promising alpha-emitting radioisotopes to fight cancers Contract for the installation of an integrated radiopharmaceutical production facility in Georgia, signed post-period end Post-period, contract with Sweden Ghana Medical Centre signed for an IntegraLab® PLUS in Ghana   Dosimetry Signed a strategic alliance for radiation therapy dosimetry solutions with ScandiDos A.B. (SDOS.ST) and made a minority investment in the company IBA’s dosimetry solutions were made compatible with Halcyon® and Ethos™ radiotherapy and adaptive therapy solutions, post-period end Expanded IBA’s myQA® iON technology into Radiation Therapy, post-period end   Outlook IBA has continued to perform well across all business units in 2022 to date and this momentum is expected to persist for the remainder of the year and beyond. The pipeline remains highly active in all businesses, underpinning visibility for the period ahead. Whilst some supply chain and inflation related challenges remain, we are seeing gradual improvements and as a business, we continue to mitigate macroeconomic pressures. With an exceptionally strong balance sheet, we are continuing with our extensive investment plan to bolster our infrastructure, supply chain and logistics, reinforce our digital ambitions and continue to maintain our market-leading technology. Alongside this, we will look to seek value-enhancing opportunities to drive future sustainable growth.   Financial calendar Full Year Results 2023                                              23 March 2023 Business Update First Quarter 2023                        18 May 2023 General Assembly                                                     14 June 2023     Proteus®PLUS and Proteus®ONE are brand names of Proteus 235 ConformalFLASH® is a registered brand of IBA’s Proton FLASH irradiation solution currently under research and development phase.    
See more

Educational Webinar Library

The clinical value PET myocardial blood flow quantification and practical aspects of implementing a Cardiac PET Program

The clinical value of myocardial flow quantification is supported by numerous observational and clinical studies in various populations. Its use is no longer restricted to a few academic centers as the technology advances and guidelines evolves. In this webinar two leading figures in the field discussed the clinical value and practical aspects of PET quantification in cardiovascular imaging and why and how to implement this modality in your institution. What will you learn from the webinar? The practical aspects and clinical value of myocardial blood flow quantification in PET in patients with cardiovascular disease - By Piotr Slomka One of the most important advances in nuclear cardiology is the opportunity to quantify myocardial blood flow (MBF) and myocardial flow reserve (MFR) routinely as part of myocardial perfusion imaging (MPI) with PET. Dr. Slomka will review practical aspects of the MBF measurements with PET and discuss its clinical value in the management of cardiac patients. How to implement a cardiac PET myocardial perfusion imaging program ? (Due to the institution policy, the recording could not be shared) - By Sharmila Dorbala Dr. Dorbala will give an overview of the advantages of PET at identifying coronary artery disease (CAD), related workflow and current guidelines. She will also share her experience on how to implement a PET cardiac program.
See more

Brochures

Cyclone® KEY

EN CN

Synthera® +

EN RU CN

Cyclone® KIUBE

EN CN RU

Videos

IBA Synthera +

IBA Synthera +

Synthera®+ remains the most compact module on the market: up to 3 synthesizers can fit into a standard hot cell. Synthera®+ and Synthera®+ HPLC have both been fully redesigned to meet the most demanding production schedule of different radiotracers without opening the hot cell (less intervention, more safety). Synthera®+ can be equipped with the automatic IFP Loader (disposable production cassette dispenser) which can stack up to 4 cassettes. This allows it to perform consecutive runs of different compounds without opening the hot cell, resulting in nearly zero radiation exposure to the operator. This unique feature multiplies the capability of each module by a factor of four.

-

Synthera Extension

Synthera® Extension complements the functionality of the Synthera® family platform with its additional valves and a syringe driver for more complex processes such as postprocess purification in 68Ga liquid target productions* and elution of Ge/Ga generator when necessary.** [18F]NaF can also be produced on Synthera® Extension on routine basis. Additionally, diverse research applications have been developed on the Synthera® Extension as a standalone module, such as : (18F)NaF; separation/purification of 89Zr, 64Cu, 99mTc to obtain 89Zr-oxalate, 64Cu-chloride, 99mTc-pertechnetate, respectively. The module employs a re-usable support cassette where disposable tubing can be placed, which eliminates the need to use an additional IFP™ for complex syntheses.

*Patent pending on the complete liquid target process: EP15170854

***It depends on the type of generator.

Cyclone KIUBE custom Energy

Cyclone KIUBE Custom Energy

Dubai

Cyclone® KEY launch event : Dubai